CRISPR Revolutionizes CAR-T Pipeline, Expands into Autoimmune Disease Amidst Exa-cel Decision

CRISPR Therapeutics is making changes to its allogeneic CAR-T cell therapy pipeline by cutting two programs, CTX110 and CTX130, and prioritizing next-generation candidates with potential for improved clinical profiles. The company is also expanding into a new indication, autoimmune disease, while awaiting an FDA decision on its CRISPR-edited therapy exa-cel. Patients treated with CTX110 and CTX130 will be transitioned to long-term follow-up programs.